CY1120578T1 - Μιγμα πεπτιδιων - Google Patents
Μιγμα πεπτιδιωνInfo
- Publication number
- CY1120578T1 CY1120578T1 CY20181100846T CY181100846T CY1120578T1 CY 1120578 T1 CY1120578 T1 CY 1120578T1 CY 20181100846 T CY20181100846 T CY 20181100846T CY 181100846 T CY181100846 T CY 181100846T CY 1120578 T1 CY1120578 T1 CY 1120578T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptides
- peptide
- point mutation
- ras protein
- site
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 230000035772 mutation Effects 0.000 abstract 3
- 102000016914 ras Proteins Human genes 0.000 abstract 3
- 108010014186 ras Proteins Proteins 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Abstract
Αποκαλύπτεται ένα μίγμα πεπτιδίων κατάλληλο για εκμαίευση μιας ανοσιακής απόκρισης. Αυτό περιλαμβάνει ένα πρώτο και ένα δεύτερο πεπτίδιο, που αντιστοιχεί κάθε ένα σε ένα θραύσμα της πρωτεΐνης RAS. Κάθε ένα από τα πρώτα και δεύτερα πεπτίδια περιλαμβάνει μία περιοχή τουλάχιστον των 8 αμινοξέων η οποία συμπεριλαμβάνει τη θέση 13 της πρωτεΐνης RAS. Κάθε μία από τις εν λόγω περιοχές των πρώτων και δεύτερων πεπτιδίων έχει ανεξαρτήτως τουλάχιστον 6 κατάλοιπα αμινοξέων, άλλα από την εν λόγω θέση 13, τα οποία είναι ταυτόσημα ως προς την αντίστοιχη περιοχή της πρωτεΐνης RAS. Κάθε ένα από τα πρώτα και τα δεύτερα πεπτίδια έχει μια μετάλλαξη σημείου στο αμινοξύ που αντιστοιχεί στην εν λόγω θέση 13. Η μετάλλαξη σημείου του πρώτου πεπτιδίου είναι διαφορετική από τη μετάλλαξη σημείου του δεύτερου πεπτιδίου.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196333 | 2013-12-09 | ||
| EP14828148.8A EP3079715B1 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
| PCT/EP2014/077033 WO2015086590A2 (en) | 2013-12-09 | 2014-12-09 | A peptide mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120578T1 true CY1120578T1 (el) | 2019-07-10 |
Family
ID=49765823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100846T CY1120578T1 (el) | 2013-12-09 | 2018-08-10 | Μιγμα πεπτιδιων |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US9775892B2 (el) |
| EP (5) | EP3363457A1 (el) |
| JP (2) | JP6781403B2 (el) |
| KR (1) | KR20160097290A (el) |
| CN (1) | CN105980403A (el) |
| AU (2) | AU2014363643B2 (el) |
| BR (1) | BR112016013138A2 (el) |
| CA (1) | CA2933126A1 (el) |
| CL (4) | CL2016001405A1 (el) |
| CY (1) | CY1120578T1 (el) |
| DK (1) | DK3079715T3 (el) |
| ES (1) | ES2682038T3 (el) |
| HR (1) | HRP20181213T1 (el) |
| HU (1) | HUE039840T2 (el) |
| IL (1) | IL246007B2 (el) |
| LT (1) | LT3079715T (el) |
| MX (1) | MX2016007429A (el) |
| PL (1) | PL3079715T3 (el) |
| PT (1) | PT3079715T (el) |
| RS (1) | RS57623B1 (el) |
| RU (1) | RU2016127327A (el) |
| SG (2) | SG10201811172PA (el) |
| SI (1) | SI3079715T1 (el) |
| WO (1) | WO2015086590A2 (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3079715T (pt) | 2013-12-09 | 2018-08-02 | Targovax Asa | Uma mistura de péptidos |
| WO2015169804A1 (en) | 2014-05-06 | 2015-11-12 | Targovax As | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| CN117224710A (zh) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
| EP3641807A4 (en) * | 2017-06-22 | 2021-04-21 | The Westmead Institute For Medical Research | ADOPTIVE T-CELL THERAPY 2 |
| TW202015719A (zh) * | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| KR20210049119A (ko) * | 2018-08-22 | 2021-05-04 | 프레드 헛친슨 켄서 리서치 센터 | Kras 또는 her2 항원을 표적으로 하는 면역요법 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2021009633A1 (en) * | 2019-07-12 | 2021-01-21 | Massey University | Synthetic chromatin vaccine |
| WO2021087840A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| KR102515083B1 (ko) | 2020-12-24 | 2023-03-29 | 부산대학교 산학협력단 | 폴더블 페로브스카이트 태양전지 및 이의 제조 방법 |
| WO2022171032A1 (zh) * | 2021-02-10 | 2022-08-18 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| KR20140067141A (ko) | 2002-12-16 | 2014-06-03 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
| EP1760089B1 (en) | 2005-09-05 | 2009-08-19 | Immatics Biotechnologies GmbH | Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine |
| SG170763A1 (en) * | 2006-03-27 | 2011-05-30 | Globeimmune Inc | Ras mutation and compositions and methods related thereto |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| PT3079715T (pt) | 2013-12-09 | 2018-08-02 | Targovax Asa | Uma mistura de péptidos |
| WO2015169804A1 (en) | 2014-05-06 | 2015-11-12 | Targovax As | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
-
2014
- 2014-12-09 PT PT148281488T patent/PT3079715T/pt unknown
- 2014-12-09 SG SG10201811172PA patent/SG10201811172PA/en unknown
- 2014-12-09 PL PL14828148T patent/PL3079715T3/pl unknown
- 2014-12-09 AU AU2014363643A patent/AU2014363643B2/en active Active
- 2014-12-09 DK DK14828148.8T patent/DK3079715T3/en active
- 2014-12-09 WO PCT/EP2014/077033 patent/WO2015086590A2/en active Application Filing
- 2014-12-09 RU RU2016127327A patent/RU2016127327A/ru not_active Application Discontinuation
- 2014-12-09 RS RS20180907A patent/RS57623B1/sr unknown
- 2014-12-09 EP EP18166279.2A patent/EP3363457A1/en active Pending
- 2014-12-09 KR KR1020167018341A patent/KR20160097290A/ko not_active Application Discontinuation
- 2014-12-09 MX MX2016007429A patent/MX2016007429A/es unknown
- 2014-12-09 US US15/102,681 patent/US9775892B2/en active Active
- 2014-12-09 SG SG11201604644QA patent/SG11201604644QA/en unknown
- 2014-12-09 EP EP18164079.8A patent/EP3357505A1/en active Pending
- 2014-12-09 EP EP18166278.4A patent/EP3369432A1/en active Pending
- 2014-12-09 LT LTEP14828148.8T patent/LT3079715T/lt unknown
- 2014-12-09 EP EP14828148.8A patent/EP3079715B1/en active Active
- 2014-12-09 CN CN201480074531.3A patent/CN105980403A/zh active Pending
- 2014-12-09 HU HUE14828148A patent/HUE039840T2/hu unknown
- 2014-12-09 JP JP2016557194A patent/JP6781403B2/ja active Active
- 2014-12-09 SI SI201430776T patent/SI3079715T1/en unknown
- 2014-12-09 CA CA2933126A patent/CA2933126A1/en not_active Abandoned
- 2014-12-09 BR BR112016013138-0A patent/BR112016013138A2/pt not_active Application Discontinuation
- 2014-12-09 ES ES14828148.8T patent/ES2682038T3/es active Active
- 2014-12-09 EP EP18166281.8A patent/EP3363458A3/en not_active Withdrawn
-
2016
- 2016-06-02 IL IL246007A patent/IL246007B2/en unknown
- 2016-06-08 CL CL2016001405A patent/CL2016001405A1/es unknown
-
2017
- 2017-03-17 US US15/461,837 patent/US10335473B2/en active Active
- 2017-08-02 US US15/667,288 patent/US10456457B2/en active Active
- 2017-09-27 US US15/716,861 patent/US10596239B2/en active Active
-
2018
- 2018-01-26 CL CL2018000232A patent/CL2018000232A1/es unknown
- 2018-01-26 CL CL2018000226A patent/CL2018000226A1/es unknown
- 2018-01-26 CL CL2018000238A patent/CL2018000238A1/es unknown
- 2018-07-30 HR HRP20181213TT patent/HRP20181213T1/hr unknown
- 2018-08-10 CY CY20181100846T patent/CY1120578T1/el unknown
-
2019
- 2019-03-20 AU AU2019201937A patent/AU2019201937B2/en active Active
- 2019-10-04 JP JP2019183442A patent/JP2020023525A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120578T1 (el) | Μιγμα πεπτιδιων | |
| CY1122079T1 (el) | Πρωτεϊνες επαναληψης διπεπτιδιου ως θεραπευτικος στοχος στις νευροεκφυλιστικες νοσους με επεκταση επαναληψης των εξανουκλεοτιδιων | |
| CY1124867T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| CY1120909T1 (el) | Πολυπεπτιδια που περιεχουν fc με μεταβληθεισα γλυκοζυλιωση και μειωμενη συντελεστικη λειτουργια | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| CY1124157T1 (el) | Προσδετες δικυκλικου πεπτιδιου ειδικοι για μτ1-mmρ | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CL2017003228A1 (es) | Fragmentos mutantes de proteína ras | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| EA202090974A1 (ru) | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы | |
| UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
| PH12015502612B1 (en) | Influenza virus vaccines and uses thereof | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| CY1123303T1 (el) | Συστημα διπλης σιστρονικης βακτηριακης εκφρασης | |
| BR112018069890A2 (pt) | polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112018071107A2 (pt) | composições e métodos para a detecção de proteínas da célula hospedeira | |
| DK3630977T3 (da) | Fremgangsmåder og sammensætninger til at fremme produktionen af proteiner indeholdende ikke-naturlige aminosyrer | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
| CY1119741T1 (el) | Συσκευη και μεθοδος για τον καθαρισμο δοχειων με μαχαιρια αερος | |
| EA201790946A1 (ru) | Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы | |
| BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
| PE20180162A1 (es) | Polipeptidos dirigidos a la fusion de vih |